For intensive insulin treatment, however, the DCCT/EDIC (Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study) research group yielded persistent benefits up to 18 years after its application regarding the diabetic nephropathy [16]. This evidence concerns the gene INS and diabetes mellitus.